Simcere Pharmaceutical Group Limited
先聲藥業集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock code: 2096)

ANNOUNCEMENT OF INTERIM RESULTS FOR THE SIX MONTHS ENDED JUNE 30, 2026

FINANCIAL HIGHLIGHTS

For the six months ended June 30, 2026, the Group recorded the following unaudited financial results:

- Revenue was RMB4,580 million, representing an increase of 27.8% as compared to RMB3,585 million for the same period of 2025.
- Revenue from the innovative pharmaceutical business[1] was RMB3,887 million, accounting for 84.9% of the total revenue and representing an increase of 34.1% as compared to RMB2,898 million for the same period of 2025.
- Revenue of the Group was mainly derived from the therapeutic areas where its businesses are focused. Of which, revenue from the field of neuroscience was RMB2,009 million, accounting for 43.9% of the total revenue and representing an increase of 60.9% as compared to RMB1,249 million for the same period of 2025. Revenue from the field of anti-oncology was RMB925 million, accounting for 20.2% of the total revenue and representing an increase of 5.8% as compared to RMB874 million for the same period of 2025. Revenue from the field of autoimmune was RMB1,210 million, accounting for 26.4% of the total revenue and representing an increase of 37.8% as compared to RMB878 million for the same period of 2025. Revenue from other fields was RMB436 million, accounting for 9.5% of the total revenue and representing a decrease of 25.2% as compared to RMB584 million for the same period of 2025.
- Profit attributable to equity shareholders of the Company was RMB829 million, representing an increase of RMB228 million or 37.9% as compared to RMB601 million for the same period of 2025. Adjusted profit attributable to equity shareholders of the Company[2] was RMB964 million, representing an increase of RMB316 million or 48.7% as compared to RMB649 million for the same period of 2025.

---

1 Includes license income.

2 The adjusted profit attributable to equity shareholders of the Company is defined by the Group as profit attributable to equity shareholders of the Company adjusted for the following items: (i) net realized and unrealized gain/(losses) on financial assets at fair value through profit or loss; (ii) net realized and unrealized gain on associates at fair value through profit or loss; (iii) interest expenses arising from redemption liabilities; and (iv) income tax effect related to the above items.

3 In October 2025, the Group completed the acquisition of Xianwei (Hainan) Biotechnology Co., Ltd., and the acquisition was deemed as a business combination under common control of the Group in accordance with the Hong Kong Accounting Standards. The Group's financial information for the 1H 2025 has been restated accordingly to comply with relevant accounting standards.

The board (the "**Board**") of directors (the "**Directors**") of Simcere Pharmaceutical Group Limited (the "**Company**") is pleased to announce the unaudited condensed consolidated financial results of the Company together with its subsidiaries (collectively the "**Group**") for the six months ended June 30, 2026 (the "**Reporting Period**" or the "**Period**"), together with the comparative figures for the same period in 2025. The unaudited condensed consolidated financial information for the Reporting Period have been reviewed by the audit committee of the Company (the "**Audit Committee**").

GROUP OVERVIEW

The Group is an innovation and R&D-driven pharmaceutical company with capabilities in R&D, production and professional marketing. The Group primarily focuses on the areas of neuroscience, anti-oncology, autoimmune and anti-infection, with forward-looking layout of disease areas that have significant clinical needs in the future, aiming to achieve the corporate mission of "born for the patients".

The Group has ten innovative drugs in total approved for marketing in the focus areas. As of June 30, 2026, the Group has various products recommended in guidelines and pathways issued by over 100 government authorities or prestigious professional associations, and over 45 products have been included in the National Reimbursement Drug List (the "**NRDL**").

The Group has entered into overseas licenses with leading international pharmaceutical corporates, including AbbVie, Boehringer Ingelheim and Ipsen, for five in-house R&D innovative drugs, with the total transaction amount exceeding US$4,600 million. This fully demonstrates our global partners' recognition of the Group's in-house R&D capabilities, the quality of our innovation pipelines, and the global market potential of our products. It also lays the foundation for the global development and value realization of our innovative achievements, serving as a key driver of the Group's sustainable growth.

The Group continues to strengthen the establishment of innovative pharmaceutical R&D capability, and has established R&D innovation centers in Shanghai, Nanjing, Beijing, Boston and Hong Kong, as well as a State Key Laboratory of Neurology and Oncology Drug Development. The Group's R&D system covered functions of the whole process from drug discovery, pre-clinical development, clinical trial to registration application and filing, and owns leading platforms of protein engineering, PAb/TCE, ADC, messenger ribonucleic acid (mRNA), AI-aided drug discovery and protein degradation. As of June 30, 2026, the Group had a R&D team of approximately 1,000 personnel in total with approximately 214 doctors and 520 masters.

The Group has a nationwide marketing network and leading commercialization capability, and will continuously strengthen its professional marketing capability, so as to enhance the coverage and accessibility of medicines. As of June 30, 2026, the Group's sales department, which was divided into four business units (neuroscience, antioncology, autoimmune & comprehensive and retail business) and other support departments had a total of approximately 4,400 personnel across 31 provinces, municipalities and autonomous regions in China, with its products covering over 3,600 Class III hospitals, approximately 17,000 other hospitals and medical institutions as well as more than 2,600 medium-to-large-scale national or regional chain pharmacies.

The Group continues to strengthen its protection of intellectual property rights. For the six months ended June 30, 2026, the Group had 204 new invention patent applications (including domestic and overseas unpublished patent applications). As of June 30, 2026, the Group has accumulatively obtained 364 invention patents, including 99 utility model patents and 41 design patents.

The Group has established manufacturing infrastructures and quality management systems in line with international standards and has continuously improved its manufacturing capabilities of pharmaceuticals. The Group has put into operation six PRC GMP certified production facilities for the manufacturing of its pharmaceutical products, and has received the EU GMP certification or passed the U.S. Food and Drug Administration ("**FDA**") inspection for some of its production workshops.

Driven by its in-house R&D efforts and synergistic innovation, the Group has established strategic cooperation partnerships with many innovative companies, research institutes and clinical centers at home and abroad, exploring multiple collaborative modes in various aspects such as cooperative R&D and achievement transfer, and continuously developing products that address significant clinical needs and have commercial potential. The Group has established the Scientific Advisory Board (SAB) comprising over 10 world-renowned scientists in the areas of neuroscience, anti-oncology and autoimmune, etc., so as to bring their professional capabilities and industrial experiences to provide scientific advice for the Group's early drug discovery and clinical development, providing continuous strategic support for global innovation and R&D.

MAJOR PRODUCTS

Neuroscience Products	Sanbexin® (Edaravone and Dexborneol Concentrated Solution for Injection)
	Sanbexin® sublingual tablets (Edaravone and Dexborneol sublingual tablets)
	QUVIVIQ® (daridorexant hydrochloride tablets)
Anti-oncology Products	Endostar® (Recombinant Human Endostatin Injection)
	ENWEIDA® (Envafolimab Injection)
	COSELA® (Trilaciclib Hydrochloride for Injection)
	ENLITUO® (Cetuximab Beta Injection)
	ENZESHU® (Suvemcitug Injection)
Autoimmune Products	Iremod® (Iguratimod Tablets)
	ANTINE® (Diclofenac Sodium Sustained Release Capsules/Gel)
Anti-infection Products	XIANNUOXIN® (Simnotrelvir Tablets/Ritonavir Tablets (co-packaged))

MANAGEMENT DISCUSSION AND ANALYSIS

INDUSTRY REVIEW

In the first half of 2026, the pharmaceutical industry of China entered a new phase of innovative transformation, advancing comprehensively toward "high-quality development" . In recent years, a series of policies supporting the development of innovative drugs have been successively introduced and gradually implemented, with the policy framework covering clinical review, pricing mechanism, payment system and clinical application continuously improved. Among them, the dynamic adjustment mechanism of the medical insurance catalog has been continuously optimized, providing a clear path for the access of innovative drugs; diversified payment models are also in the stage of gradual exploration, and the overall industrial development environment keeps improving. With the gradual enhancement of the innovation capability of domestic pharmaceutical enterprises, the total amount of overseas licensing transactions of Chinese pharmaceutical companies has exceeded the threshold of 100 billion US dollars, reaching a new record high. On the whole, the domestic pharmaceutical industry is in the development stage of innovation and upgrading, and has long-term growth potential and international development space.

BUSINESS REVIEW

The Group continues to advance the launch and commercialization of innovative drugs, providing momentum for long-term sustainable growth. As of the date of this announcement, the Group has ten innovative drugs that have entered the commercialization stage, namely Endostar®, Iremod®, Sanbexin®, ENWEIDA®, COSELA®, XIANNUOXIN®, ENLITUO®, Sanbexin® sublingual tablets, QUVIVIQ® and ENZESHU®. Meanwhile, the New Drug Application ("**NDA**") of Xianlinda® (adults/adolescents tablet formulation, children tablet formulation, children's granule), Leruiping® Pumecitinib Gel, new indication for ENWEIDA®'s biliary tract cancer and new indication for Endostar®'s malignant thoracoabdominal effusions were accepted.

Addressing the unmet clinical needs, the Group keeps on advancing the R&D pipelines of innovative drugs. As of the date of this announcement, the Group has over 60 R&D pipelines of innovative drugs. The Group added three investigational new drug applications ("**IND(s)**")[1], completed eleven First-in-human ("**FIH(s)**")/First-Patient-In ("**FPI(s)**")[2] and five Last-Patient-In ("**LPI(s)**")[3].

---

[1] Three INDs added namely SIM0532 (advanced solid tumors, March 2026, China), SIM0613 (advanced solid tumors, May 2026, China) and SIM0689 (advanced solid tumors, June 2026, China).

[2] Eleven studies completed FIH/FPI, namely SIM0610 (advanced solid tumors, phase I, January 2026, China), SIM0811 (phase I, February 2026, China), SIM0278 (Alopecia Areata, phase II, February 2026, the United States), Deuterated Remdesivir Hydrobromide dry suspension formulation (Respiratory Syncytial Virus (RSV) infection in infants and young children, phase III, March 2026, China), Deuterated Remdesivir Hydrobromide dry suspension formulation (Respiratory Syncytial Virus (RSV) infection in infants and young children, phase I-BE, April 2026, China), SIM0532 (advanced solid tumors, phase I, May 2026, China), SIM0278 (Lupus Nephritis, phase II, June 2026, China), SIM0613 (advanced solid tumors, phase I, June 2026, China), COSELA® (Limited-stage small cell lung cancer, phase III, June 2026, China), ENLITUO® (First-line treatment of colorectal cancer, phase III, June 2026, China) and SIM0689 (advanced solid tumors, phase I, July 2026, China).

[3] A total of five studies completed LPI, namely ENWEIDA® (Non-Small Cell Lung Cancer perioperative, phase III, May 2026, China), SIM0278 (atopic dermatitis, phase II, May 2026, China), SIM0811 (phase I, June 2026, China), SIM0270 (Second-line treatment of breast cancer, phase III, June 2026, China) and Zemprocitinib (ankylosing spondylitis, phase III, July 2026, China).

During the Reporting Period and up to the date at this announcement, the Group made a series of advances in respect of its product candidates, business operations and business development, including the following key milestones and achievements:

In August 2026	The Group entered into a strategic cooperation with Ruiyang (Shandong) Biopharmaceutical Co., Ltd. (hereinafter referred to as "Ruiyang Bio") regarding the domestic Category 1 new biological drug, Clesrovimab Injection. Under the agreement, Simcere Pharmaceutical will obtain the exclusive commercialization rights of Clesrovimab in the Greater China region. At present, the New Drug Application for Clesrovimab has been accepted by the Center for Drug Evaluation (CDE) of the National Medical Products Administration and has been included in the priority review and approval process.
In July 2026	Sanbexin® (Edaravone and Dexborneol Concentrated Solution for Injection), a Category 1 innovative drug independently developed by the Group, has been officially included in the new National Essential Medicines List. This will significantly improve terminal accessibility of the pharmaceutical products.
In July 2026	The Group has entered into a global drug discovery and development collaborative agreement with Schrödinger, Inc.. The two parties will fully leverage their respective strengths in the R&D of drugs, focus on unmet clinical needs, and building on our expertise in relevant therapeutic areas, jointly advance the R&D of innovative drugs.
In June 2026	The Group entered into an exclusive promotion service agreement with PrimeGenX Therapeutics Co., Ltd. (北京普祺醫藥科技股份有限公司), pursuant to which, the Group will obtain the exclusive promotion rights for Pumecitinib Gel for all dermatology indications in Mainland China, Hong Kong and Macau.
In June 2026	The Group has entered into a collaborative research agreement with Stanford University School of Medicine (斯坦福大學醫學院) to jointly advance an exploratory study in the field of respiratory medicine aimed at developing innovative therapies for patients with idiopathic pulmonary fibrosis (IPF).
In January 2026	The Group entered into an exclusive licensing agreement (the "**Agreement**") with Boehringer Ingelheim (勃林格殷格翰). Under terms of the Agreement, Boehringer Ingelheim would have the exclusive global rights, outside of Greater China, of SIM0709, a TL1A/IL-23p19 bispecific antibody for inflammatory bowel disease.

For details of each milestone above, please refer to the following sections of this announcement and, where appropriate, previous announcements of the Company published on the websites of The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") and the Company.

SUMMARY OF PRODUCT PIPELINES

As of the date of this announcement, 10 drug candidates are in NDA/pivotal clinical stage[1] and 14 molecules entered early clinical stage. The forms of innovative drugs under development contain monoclonal antibodies, bispecific antibodies, multi-specific antibodies, fusion proteins, antibody-drug conjugates ("**ADC**") and small molecule drugs, etc. The extensive pipeline reserves have huge clinical and commercialization potential, which are expected to help more patients.

The table below summarizes the therapeutic targets, therapeutic areas, rights and development of principal R&D pipelines of the Group as of the date of this announcement.

[1] Including products with commercial rights, namely ENWEIDA®, Xianlinda®, LNK01001 and TGRX-326.


Territory
Product candidate (Target/Mechanism)
Pre-clinical
IND
Phase I
Phase II
Phase III
NDA/BLA
Anti-Oncology
Global
Endostar® New indication (Angiogenesis)
Thoracoabdominal effusions (COREMAP study)
China (commercialization right)
Enweida (恩维達®) New indication (PD-L1)
Advanced biliary tract cancer
Non-small cell lung cancer (perioperative)
TMB-H Solid tumors
Global
SIM0270 (SERD)
Breast cancer
China (commercialization right)
Denlorlatinib (ALK/ROS1)
Non-small cell lung cancer
China (commercialization right)
ENLITUO® New indication (EGFR)
First-line colorectal cancer
China (commercialization right)
COSELA® New indication (CDK4/6)
Limited stage small cell lung cancer
Global
SIM0237 (PD-L1/IL15v bispecific antibody)
Non-muscle invasive bladder cancer
China
Enzeshu® New indication (VEGF)
Third-line refractory metastatic colorectal cancer
China (Option to license from AbbVie for rights outside Greater China)
SIM0500 (GPRC5D/BCMA/CD3 trispecific antibody)
Multiple myeloma (China and U.S.)
China
SIM0395 (PI3K/mTOR)
Glioblastoma
(GBM AGILE study)
Global
SIM0508 (Polθ)
Solid tumors (China and U.S.)
China (licensed-out to NextCure outside of China)
SIM0505 (CDH6 ADC)
Solid tumors (China and U.S.)
Global
SIM0686 (FGFR2b ADC)
Solid tumors (China and U.S.)
Global
SIM0609 (CDH17 ADC)
Solid tumors (China and U.S.)
Global
SIM0610 (EGFR/cMet ADC)
Solid tumors
Global
SIM0532 (PanRAS)
Solid tumors
China (licensed-out to Ipsen outside of China)
SIM0613 (LRRC15 ADC)
Solid tumors
Global
SIM0689 (PD-1/VEGF)
Solid tumors
Global
SIM0518 (ALK)
Solid tumors
China
SIM0323 (CD80/IL2)
Solid tumors
Global
SIM0688 (B7H3/cMet ADC)
Solid tumors
Global
SIM0616 (STEAP1/PSMA/CD3)
Solid tumors
Global
SIM0611 (EGFR/cMet ADC(NMTi))
Solid tumors
Neuroscience
Global
Sanbexin® injection New Indication (Free radicals and inflammatory cytokines)
ICH
Global
Sanbexin® sublingual tablets (Free radicals and inflammatory cytokines)
Post stroke cognitive impairment
AIS (U.S.)
Global
SIM0811 (PLG)
AIS, MI, etc.
Global
SIM0815 (brainpenetration-Aβ bispecific antibody)
Alzheimer's disease
Autoimmune
China
Leruiping® Rademikibart (IL-4Rα)
AD
Asthma
China (commercialization right)
Pumecitinib Gel (JAK)
AD
China (commercialization right)
Zemeixin® Zemprocitinib (JAK1)
RA
AS
China (licensed-out to Almirall outside of China)
SIM0278 (IL-2mu-Fc)
AD
LN
Alopecia areata (U.S.)
China (licensed-out to Boehringer Ingelheim outside of China)
SIM0709 (TL1A/IL23p19)
Inflammatory bowel disease
Global
SIM0712 (STAT6 PROTAC)
AD, COPD, Asthma, etc
Global
SIM0725 (CD122)
Vitiligo, AA, etc
Global
SIM0708 (IL-4Rα ADC)
AD, COPD, Asthma, etc
Global
SIM0721
LN、IgAN, etc
Global
SIM0722
AD, COPD, Asthma, etc
Anti-infective
China (commercialization right)
Xianlinda® Deunoxavir Marboxil (PA)
Influenza (adult/adolescent)
Influenza (child)
Post-exposure prevention of influenza type A and B (2 years old and above)
China (commercialization right)
Deuterated Remdesivir Hydrobromide Dry Suspension (RdRp)
Respiratory syncytial virus infection
Development status of the Group
Development status of partner(s)

PROGRESS OF R&D AND CLINICAL MILESTONES

INNOVATIVE DRUGS AT THE COMMERCIALIZATION STAGE

Up to the date of this announcement, the Group has successfully expanded its commercialized portfolio of innovative drugs into ten: Endostar®, Iremod®, Sanbexin®, ENWEIDA®, COSELA®, XIANNUOXIN®, ENLITUO®, Sanbexin® sublingual tablets, QUVIVIQ® and ENZESHU®, spanning over multiple areas, including neuroscience, anti-oncology, autoimmune and anti-infection, which have significant market potentials and synergistic effects.

MILESTONES AND ACHIEVEMENTS DURING THE REPORTING PERIOD

Neuroscience Products

Sanbexin® (Edaravone and Dexborneol Concentrated Solution for Injection)

Sanbexin® is a category I innovative drug developed by the Group with proprietary intellectual property right used to treat acute ischemic stroke ("**AIS**"). Sanbexin® was approved for marketing in China in July 2020 and has been included in the NRDL since December 2020 and renewed its inclusion in the NRDL in November 2024.

For the six months ended June 30, 2026, Sanbexin® Injection, accounting for approximately 34% of the market share in stroke injection, covered approximately 1.07 million patients and over 5,900 medical institutions.

Milestone of Commercialization

- In July 2026, Sanbexin® was officially included in the National Essential Medicines List (2026 Edition). According to the relevant management regulations for essential medicines, public medical institutions at all levels nationwide are required to equip and give priority to the use of medicines listed in the catalog. The inclusion is highly beneficial for Sanbexin® to break through the limitations of Class Grade III Type A (3A) hospitals, accelerate market penetration into county-level and grassroot healthcare markets, and expand terminal prescription scenarios. Compounded with its existing medical insurance qualifications, this milestone will further enhance the accessibility of the medicine and solidify the Group's competitive edge in the therapeutic field of acute stroke.

Data Release

- In January 2026, two major research findings were published. Firstly, a sub-group analysis based on the EXPAND study was published in JAHA, confirming that Edaravone Dexborneol improves 90-day functional outcomes and reduces mortality rate in AIS patients with large core myocardial infarction and poor prognosis. Secondly, the TASTE-2 study was published in BMJ, confirming that Edaravone Dexborneol combined with EVT significantly improves long-term functional prognosis in patients with acute large vessel occlusion stroke with good safety.

- In February 2026, relevant updates were presented at ISC 2026. An analysis pooling 4 RCTs with a total of 3,627 patients confirmed that Edaravone Dexborneol improves functional outcomes in AIS patients. Additional research suggested the drug may simultaneously improve vascular dementia-related brain injury and cardiac injury.

- In May 2026, multiple clinical data sets were released at ESOC 2026. Two overseas analyses consistently validated that the product improves functional recovery and delivers comprehensive benefits in AIS patients. A real-world study from Xuanwu Hospital provided further evidence supporting the efficacy of Edaravone Dexborneol in improving functional prognosis in patients with posterior circulation stroke.

Sanbexin® sublingual tablets (Edaravone and Dexborneol sublingual tablets)

Sanbexin® sublingual tablets is a brain cytoprotective agent composed of edaravone and dexborneol, two active ingredients with synergistic anti-oxidant and anti-inflammatory effects, which can significantly reduce brain cell injury or impairment caused by AIS. Such unique sublingual tablets formulation can quickly disintegrate once in contact with the saliva under the tongue and can be absorbed into the blood through the sublingual venous plexus, increasing the flexibility of stroke treatment. Sanbexin® sublingual tablets can form a sequential therapy combined with Sanbexin® injection, enabling patients to receive a complete course of treatment in and outside of the hospital.

In December 2024, Sanbexin® sublingual tablets was approved for marketing in China, aiming at improving the neuro symptoms, the daily living abilities and dysfunction caused by AIS. In August 2024, Sanbexin® sublingual tablets was granted the "Breakthrough Therapy" designation by the FDA, which was the first innovative drug in the global stroke treatment sector receiving such designation and the first innovative drug in the Chinese neuroscience sector receiving such designation.

Data Release

- In May 2026, the "Research Progress of Edaravone Dexborneol in Brain Cell Protection for Acute Ischemic Stroke" was published in the Chinese Journal of Stroke. The article pointed out that, compared with most single-target brain-protection drugs, Edaravone Dexborneol acts on multiple pathological mechanisms of ischemic stroke. The drug has been developed into two dosage forms: an injection suitable for standardized in-hospital treatment of acute ischemic stroke, and a sublingual tablet that meets the need for rapid drug administration in pre-hospital and primary care settings. This multi-dosage-form strategy endows Edaravone Dexborneol not only with pharmacological advantages in brain protection, but also with outstanding clinical applicability and accessibility.

QUVIVIQ® (daridorexant hydrochloride tablets)

QUVIVIQ® is a dual orexin receptor antagonist ("**DORA**"). Unlike traditional sedative-hypnotic drugs that promote sleep by sedating the brain, QUVIVIQ® works by blocking the binding of wake-promoting orexin neuropeptides (orexin A and orexin B) to their receptors. As a result, QUVIVIQ® reduces wake drive and facilitates the onset of sleep, decreases wake time after sleep onset, and extends total sleep duration, without altering sleep architecture. Clinical study results have shown that QUVIVIQ® has a favorable safety and tolerability profile, with no evidence of rebound insomnia, withdrawal symptoms, or drug abuse. In addition to improving nighttime sleep in adults with insomnia disorder, QUVIVIQ® also enhances daytime functioning. It is the only DORA insomnia medication approved by the European Medicines Agency (EMA) for improving daytime functioning. The Guidelines for the Diagnosis and Treatment of Insomnia Disorders in China (2nd Edition), published in 2025, strongly recommend QUVIVIQ® with Grade A evidence. In June 2025, QUVIVIQ® was approved for marketing in China for the treatment of adult patients with insomnia characterised by difficulty falling asleep and/or difficulty staying asleep, and is not classified as a psychotropic substance. Previously, QUVIVIQ® has been approved for marketing in 38 countries including the United States, the United Kingdom, Switzerland, Canada, as well as in the Hong Kong SAR of China.

Data Release

- In March 2026, Idorsia announced that daridorexant had achieved positive results in a Phase II dose-exploration study (NCT05423717) in children with sleep disorders. The study demonstrated that daridorexant produced statistically significant, dose-dependent improvements in sleep in children and adolescents with insomnia, and confirmed its favourable safety and tolerability profile in the paediatric population for the first time. Currently, there are no FDA-approved treatments for paediatric insomnia in the United States, and clinical treatment options are extremely limited. These results not only further expand the evidence base for daridorexant in the treatment of insomnia but also offer new hope for the clinical field of paediatric insomnia, where there has long been an unmet need.

- In March 2026, the European Psychiatric Association 2026 Congress (EPA 2026) presented preliminary data from a study of 50 mg daridorexant in adults with attention-deficit/hyperactivity disorder (ADHD) and comorbid insomnia. The study enrolled 30 patients with ADHD and comorbid insomnia and aimed to assess the effects of daridorexant on insomnia symptoms and attention. The results showed that following treatment with daridorexant, 62.5% of patients achieved clinically significant improvement in insomnia symptoms (a reduction of ≥7 points in the Insomnia Severity Index (ISI)).

- In June 2026, the "Chinese Expert Consensus on the Treatment of Insomnia with Daridorexant", jointly formulated by 34 multidisciplinary experts led by Professor Lu Lin, an Academician of the Chinese Academy of Sciences and Professor at Peking University Sixth Hospital, was officially published. The consensus comprises 17 recommendations. It not only clarifies the dual benefits of daridorexant in improving night-time sleep and restoring daytime functioning, but also provides systematic and practical clinical guidance on key issues such as the target patient population, dosage selection, management of special patient groups, and strategies for switching medications and discontinuing treatment, thereby offering comprehensive guidance on the treatment of insomnia, ranging from mechanisms of action to clinical practice.

Oncology Products

Endostar® (Recombinant Human Endostatin Injection)

Endostar® is the first anti-angiogenic targeted drug in China and the first endostatin approved for sale worldwide. Endostar® has been included in the NRDL since 2017 and is recommended as a first-line treatment for patients with advanced non-small cell lung cancer ("**NSCLC**") by a number of oncology clinical practice guidelines issued by the National Health Commission of the PRC ("**NHC**"), Chinese Medical Association (中華醫學會) and Chinese Society of Clinical Oncology ("**CSCO**"). Also, it has been included in the recommendations by various guidelines in relation to nasopharyngeal carcinoma, melanoma, esophageal carcinoma and osteosarcoma. In December 2025, Endostar® has been successfully included in the catalog of routine medicines covered by medical insurance (as a drug negotiated outside the cooperative period).

Registration Progress

- In February 2026, the NDA for the treatment of thoracoabdominal effusions has been accepted by the NMPA.

Data Release

- In June 2026, a study on Endostar® was selected for presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The tile of the study was as follow: A Phase II Study of the Efficacy and Safety of Continuous Intra-arterial Cisplatin Combined with Recombinant Human Endostatin in Conjunction with Systemic Chemotherapy for the Treatment of Osteosarcoma.

- In July 2026, a study on Endostar® was selected for presentation at the 2026 European Society for Medical Oncology Gastrointestinal Cancers Conference (ESMO-GI). The title of the study was as follow: Final analysis of a Phase III study: Comparasion of treatment in patients with malignant pleural effusion or malignant ascites by cisplatin plus Endostar and cisplatin plus placebo (the COREMAP study).

ENWEIDA® (Envafolimab Injection)

ENWEIDA® is the world's first PD-(L)1 antibody to be administered by subcutaneous injection approved for marketing. Its unique method of injection differentiates itself from other PD-(L)1 products currently on the market, with the differentiation advantages of short administration time and good safety. In March 2020, the Group entered into a tripartite cooperation agreement in relation to ENWEIDA® with 3D (Beijing) Medicines Inc. (思路迪(北京)醫藥科技有限公司) and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. (江蘇康寧傑瑞生物製藥有限公司). The Group obtained the exclusive right to promote ENWEIDA® for all oncology indications and the right of first refusal of external licensing or assignment in the Chinese mainland.

Registration Progress

- In January 2026, the NDA for the first-line treatment of unresectable or metastatic biliary tract cancer was accepted by the NMPA.

Milestone of Clinical Progress

- In May 2026, the Phase III clinical study of a new indication for ENWEIDA® in the perioperative setting of NSCLC has achieved LPI.

- The Phase II clinical study of a new indication for ENWEIDA® of TMB-H solid tumours is currently ongoing.

Data Release

- In June 2026, a total of four studies involving ENWEIDA® were selected for presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting. These included: ENWEIDA® in combination with GEMOX versus GEMOX alone as first-line treatment for Chinese patients with advanced biliary tract cancer: a randomised, open-label, multicentre, Phase III pivotal clinical trial. This study was the first Phase III registration clinical trial for first-line treatment of Chinese patients with advanced biliary tract cancer.

COSELA® (Trilaciclib Hydrochloride for Injection)

COSELA® is an effective, selective and reversiblecycl in-dependent kinases 4 and 6 (CDK4/6) inhibitor. COSELA® is the world's first-in-class comprehensive myeloprotection innovative drug that can de-administered prior to a chemotherapy. The Group entered into the exclusive license agreement with G1 Therapeutics, Inc. to obtain the development and commercialization rights of COSELA®. In February 2021, COSELA® was approved for marketing by the FDA. In July 2022, the marketing of COSELA® in China has obtained the conditional approval by the NMPA. In April 2023, the Group has obtained full rights to the sales milestones of COSELA®. In December 2023, the localization of COSELA® has been approved by the NMPA and it can be produced by the production enterprises of the Group in Haikou, Hainan Province, which further improved its accessibility to patients with cancer in China. Currently, the product has been recommended by the related key guidelines of National Comprehensive Cancer Network Guidelines (NCCN), CSCO and other organizations. In November 2024, COSELA® was successfully included in NRDL.

Registration Progress

- New indication for COSELA®, the second- and third-line treatment of extensive-stage small cell lung cancer has been approved.

Milestone of Clinical Progress

- In June 2026, the phase III clinical study of new indications of COSELA® LS-SCLC has achieved FPI.

Data Release

- In March 2026, two studies on COSELA® were selected for presentation at the European Lung Cancer Conference (ELCC), focusing on the field of extensive-stage small cell lung cancer.

- In April 2026, the "Clinical Guidelines for the Use of the Full Range of Trilaciclib for Bone Marrow Protection" was published in the Journal of Clinical Oncology.

- In June 2026, two studies on COSELA® were selected for presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The study titles were: (1) Bone marrow protection with trilaciclib in adjuvant and first-line chemotherapy for gastric adenocarcinoma and gastro-oesophageal junction adenocarcinoma: a multi-cohort study, (2) The role of trilaciclib in preventing chemotherapy-induced myelosuppression: an updated systematic review and meta-analysis.

ENLITUO® (Cetuximab Beta Injection)

ENLITUO® is a recombinant anti-epidermalgrowth factor receptor ("**EGFR**") chimeric monoclonal antibody for first-line treatment of RAS/BRAF wild-type metastatic colorectal cancer ("**mCRC**") in combination with FOLFIRI. ENLITUO® is prepared using a specific expression process, effectively avoiding glycosylation modification that may lead to hypersensitivity without black box warnings in the instruction. In June 2024, ENLITUO® was approved for marketing in China by the NMPA and is the first anti-EGFR monoclonal antibody innovative drug developed in China with independent intellectual property rights which has been approved by the NMPA for first-line treatment of mCRC. The successful launch of ENLITUO® provides high quality and affordable biological targeted remedy for Chinese mCRC patients. In November 2024, ENLITUO® was successfully included in NRDL.

Milestone of Clinical Progress

- In June 2026, the phase III clinical study of new indications of ENLITUO® of first-line colorectal cancer has achieved FPI.

Registration Progress

- In August 2026, the IND application of the new indication of ENLITUO® for first-line treatment of phase II squamous cell carcinoma of the head and neck has been approved by the NMPA.

- The ENLITUO® package leaflet was updated on May 11, 2026, with the statement "It is recommended that treatment with this product continue until the patient's disease with progression of cure." amended to "If chemotherapy is interrupted due to unacceptable toxicity caused by the chemotherapeutic agents, it is recommended that treatment with this product continue until the patient's disease with progression of cure."

Data Release

- In April 2026, the CSCO Guidelines for Colorectal Cancer 2026 (《2026 CSCO結直腸癌指南》) standardised the description of anti-EGFR monoclonal antibodies, including ENLITUO®, for first-line treatment of advanced disease, recommending their use for patients with MSS or MSI-L/pMMR who are suitable for intensive treatment and have wild-type RAS and BRAF, and who are potentially resectable, for palliative first-line treatment: for left-sided colorectal cancer – anti-EGFR monoclonal antibody + FOLFIR/FOLFOX (Grade I recommendation, Class 1A evidence); for right-sided colon cancer – anti-EGFR monoclonal antibody + FOLFIR/FOLFOX (for patients with contraindications to bevacizumab) (Grade II recommendation, Class 2A evidence).

ENZESHU® (Suvemcitug for Injection)

ENZESHU® is a next-generation recombinant humanized anti-vascular endothelial growth factor ("**VEGF**") monoclonal antibody developed by the Group and Pyxis Oncology, Inc. On June 30, 2025, ENZESHU® was approved for marketing in China. It is indicated for the treatment of recurrent ovarian cancer, fallopian tube cancer, or primary peritoneal cancer in combination with paclitaxel, liposomal doxorubicin, or topotecan in adults who have received no more than one systemic therapy after platinum resistance. ENZESHU® is the first vascular-targeting drug to demonstrate a significant OS benefit in patients with platinum-resistant ovarian cancer. In December 2025, ENZESHU® was successfully included in the 2025 edition of the NRDL.

By potently blocking the binding of VEGF to its receptor, ENZESHU® inhibits tumor angiogenesis, thereby achieving an anti-tumor effect. With a unique molecular design featuring a differentiated VEGF-binding epitope, preclinical studies have shown that ENZESHU® has significantly greater inhibitory activity against the binding of VEGF to its receptor (VEGFR2) compared to bevacizumab, as well as stronger suppression of human vascular endothelial cell proliferation. ENZESHU® exhibits enhanced biological activity and superior tumor-inhibitory effects relative to bevacizumab at the same dosage across multiple tumor models.

Milestone of Clinical Progress

- As part of the follow-up of new indication in third-line refractory metastatic colorectal cancer of trial participants for ENZESHU®, the phase III clinical trial has been approved by the CDE.

Data Release

- In June 2026, the American Society of Clinical Oncology (ASCO) Annual Meeting has announced protocol for a Phase Ib/III randomised, double-blind, placebo-controlled clinical trial (NCT07361003) of ENZESHU®. The trial is designed to evaluate the efficacy and safety of the novel anti-VEGF monoclonal antibody suvemcitug in combination with trifluridine/tipiracil (FTD/TPI) in the treatment of refractory metastatic colorectal cancer (mCRC).

Autoimmune Products

Iremod® (Iguratimod Tablets)

Iremod® is the first Iguratimod pharmaceutical product approved for marketing in the world. Iremod® has been included in the NRDL since 2017. The indication is the active rheumatoid arthritis. Iremod® is recommended as the primary therapy drug for the treatment of active rheumatoid arthritis by a number of clinical practice guidelines and pathways issued by the NHC, Chinese Medical Association, Asia Pacific League of Associations for Rheumatology and Labor and Welfare of Japan. Since its launch in 2012, Iremod® has benefited several million patients in China, which further consolidated its leading market position in the traditional DMARDs sector.

Data Release

- In June 2026, two studies on Iremod® were selected for presentation at the 2026 European League Against Rheumatism (EULAR) Annual Congress. The study titles were: 1. Dual-targeted therapy for joint and lung diseases: Efficacy of Tofacitinib Combined with Iguratimod in the Treatment of Progressive Fibrotic Rheumatoid Arthritis-associated Interstitial Lung Disease; 2. A New Treatment Approach for Reactive Arthritis: Clinical and Cytokine Responses to Iguratimod 25 mg Compared with Biologics and Conventional Therapies.

Anti-infection Products

XIANNUOXIN® (Simnotrelvir Tablets/Ritonavir Tablets (co-packaged))

XIANNUOXIN® is the first domestic 3CL small molecule anti-SARS-CoV-2 innovative drug with independent intellectual rights in China. On November 17, 2021, the Group entered into a technology transfer contract with Shanghai Institute of Materia Medica and Wuhan Institute of Virology, Chinese Academy of Sciences, pursuant to which, the Group obtained the development, production and commercialization rights on an exclusive basis of Simnotrelvir worldwide. In July 2024, XIANNUOXIN® has been reviewed and approved by the NMPA for conversions from conditional approval to regular approval, which became the first oral anti-SARS-CoV-2 innovative drug which has obtained regular approval in China.

DRUG CANDIDATES AT THE NDA TRIAL STAGE

Anti-infection Products

Xianlinda® (Deunoxavir Marboxil)[1]

Deunoxavir Marboxil is an inhibitor for influenza polymerase acidic (PA) protein. Preclinical studies have shown that Deunoxavir Marboxil demonstrates several benefits, including the absence of central nervous system side effects, no effect of food intake on oral drug absorption and higher safety dose. The entire oral dose of Deunoxavir Marboxil is merely "one tablet" and is capable of stopping influenza virus replication in 24 hours, having a prospect of bringing great convenience to a large number of patients, including child patients. In March 2025, the NDA of Deunoxavir Marboxil Tablets has been accepted by the NMPA, which can be used to treat uncomplicated influenza A and B in adults and adolescents.

Autoimmune Products

Leruiping® Rademikibart (IL-4Rα)

Rademikibart is a fully human monoclonal antibody targeting IL-4R α, a common subunit of IL-4 receptor and IL-13 receptor. By binding with IL-4R α, Rademikibart can block the functions of IL-4 and IL-13 effectively, thereby blocking the Th2 inflammatory pathway, thus achieving the goal of treating Th2 related inflammatory diseases such as atopic dermatitis and asthma.

Registration Progress

- In April 2026, the NDA of Leruiping® has been accepted by the NMPA, which can be used to treat of atopic dermatitis in adults and adolescents.

Milestone of Clinical Progress

- The Phase III clinical study of Rademikibart in asthma is underway.

[1] A product with commercial right

Data Release

- In March 2026, the Phase III clinical study of Rademikibart in adult and adolescent patients with moderate-to-severe atopic dermatitis was selected as a Late-Breaking Abstract (LBA) for an oral presentation at the 84th American Academy of Dermatology Annual Meeting. Results from the Phase III clinical study indicated that Rademikibart offered not only a rapid onset of action, but also increasingly pronounced cumulative benefits over sustained treatment, demonstrating potential for superior efficacy compared to peer products. At Week 16, response rates for EASI-75, EASI-90, and IGA 0/1 in the Rademikibart group reached 74.2%, 43.0%, and 47.7%, respectively ($p < 0.0001$), showing clear clinical benefits achieved early in treatment. By Week 52, response rates for EASI-75, EASI-90, and IGA 0/1 further increased to 96.6%, 85.3%, and 87.1%, respectively, highlighting a prominent advantage in driving deep disease remission upon continuous treatment.

Pumecitinib Gel (JAK)

Pumecitinib Gel is the world's first JAK inhibitor gel indicated for the treatment of AD. Clinical trial results for mild-to-moderate AD in adults and adolescents aged 12 and above demonstrated that, compared with the placebo, Pumecitinib Gel significantly improved patients' skin lesions and related clinical symptoms, while presenting a favorable safety and tolerability profile alongside low plasma concentration. Furthermore, Pumecitinib Gel is non-greasy, easy to apply, and spreads evenly over the skin with a gentle and soothing feel, which addresses the greasy texture common in certain traditional topical formulations and helps improve patient compliance.

Milestone of Strategic Cooperation

- In June 2026, the Group entered into an exclusive promotion service agreement with PrimeGenX Therapeutics Co., Ltd. (北京普祺醫藥科技股份有限公司) in relation to Pumecitinib Gel, where the Group will obtain the exclusive promotion rights for all dermatology indications in Mainland China, Hong Kong, and Macau.

Milestone of Clinical Progress

- In February 2026, the NDA of Pumecitinib Gel for the indication of atopic dermatitis in adults and adolescents has been accepted by the NMPA.

PHASE III CLINICAL STAGE DRUG CANDIDATES

Anti-oncology Products

SIM0270 (SERD)

SIM0270 is a second-generation oral SERD with blood-brain barrier penetration characteristics independently developed by the Group. SIM0270 was significantly more effective than fulvestrant a marketed intramuscular SERD product, in an in vivo model, comparable to the leading compound in the clinical trial phase, and reflected a brain-blood ratio significantly better than competitive compounds and showed a much better tumor inhibition effect than fulvestrant in the orthotropic model of breast cancer brain. It is expected to be used for the treatment of breast cancer with brain metastases.

Milestone of Clinical Progress

- In June 2026, the phase III clinical trial comparing SIM0270 in combination with everolimus versus investigator's choice of treatment for ER+/HER2- locally advanced or metastatic breast cancer following treatment with a CDK4/6 inhibitor achieved LPI.

Deulorlatinib (ALK/ROS1)[1]

Deulorlatinib is the latest generation of novel type 1 drug for the treatment of NSCLC driven by ALK/ROS1 positive fusion gene cooperated by the Group and Shenzhen TargetRx, Inc. (深圳市塔吉瑞生物醫藥有限公司), pursuant to which, the Group obtained the exclusive commercialization rights of the product in Chinese Mainland. Deulorlatinib has high blood-brain barrier permeability, and is effective for the treatment of NSCLC with brain metastasis.

Milestone of Clinical Progress

- In June 2026, the pre-NDA application of Deulorlatinib has been submitted.

[1] A product with commercial right

Autoimmune Products

Zemexin® Zemprocitinib (JAK1)[1]

Zemprocitinib is a highly selective JAK1 inhibitor. In March 2022, the Group entered into a cooperation agreement with Lynk Pharmaceuticals Co., Ltd. (凌科藥業(杭州)有限公司), pursuant to which the Group obtained the exclusive commercialization rights for Zemprocitinib for rheumatoid arthritis (RA) and ankylosing spondylitis ("**AS**") indications in China and will be responsible for its promotional activities following regulatory approval.

Milestone of Clinical Progress

- In July 2026, the Phase III clinical study of Zemprocitinib for the AS indication completed LPI.

Anti-infective Products

Deuterated Remdesivir Hydrobromide Dry Suspension (RdRp)

Deuterated Remdesivir Hydrobromide Dry Suspension is an oral nucleoside drug with broad-spectrum activity against RNA viruses, acting through the inhibition of viral RNA-dependent RNA polymerase (RdRp). The Phase II clinical trial in China evaluating Deuterated Remdesivir Hydrobromide Dry Suspension for the treatment of RSV infection in infants and young children aged 1–24 months (the "**Clinical Study**") has been completed. Clinical results demonstrated that the Deuterated Remdesivir Hydrobromide Dry Suspension formulation showed favorable antiviral efficacy against RSV as well as a good safety profile. Based on the positive results of the clinical study, the Deuterated Remdesivir Hydrobromide dry suspension has been granted Breakthrough Therapy drug designation by the CDE. In December 2025, the Group entered into a license agreement with Vigonvita Life Science Co., Ltd. regarding new indications for Deuterated Remdesivir Hydrobromide Dry Suspension, pursuant to which the Group will obtain the exclusive rights for Deuterated Remdesivir Hydrobromide Dry Suspension in the Greater China region for the indications of anti-RSV infection and anti-human metapneumovirus (HMPV) infection.

Milestone of Clinical Progress

- In February 2026, Deuterated Remdesivir Hydrobromide Dry Suspension initiated the Phase III clinical trial for RSV infection.

- In March 2026, the above clinical trial reached the FPI.

---

[1] A product with commercial right

PHASE I/II CLINICAL STAGE DRUG CANDIDATES (SELECTED)

Anti-oncology Products

SIM0237 (PD-L1/IL15v bispecific antibody)

SIM0237 is an anti-PD-L1 monoclonal antibody fused with IL-15/IL15R α sushi protein and developed in-house by utilizing the Group's protein engineering platform. It can block the PD1/PD-L1 immunosuppressive pathway via binding to PD-L1 and activate the immune system through its IL-15 part, thus playing a synergistic role of relieving immunosuppression and boosting the immune system to exhibit antitumor effect.

Data Release

- In March 2026, the SIM0237 Phase I/II clinical study data for the treatment of Bacillus CalmetteGuérin ("**BCG**")-unresponsive high-risk NMIBC was presented at the European Association of Urology Annual Congress 2026 (EAU 2026). As of the data cut-off date (November 28, 2025), a total of 49 patients had received intravesical instillation of SIM0237 monotherapy. Among patients with carcinoma in situ (CIS) who had at least one post-baseline tumor assessment, 80% achieved the complete response (CR). Among patients with papillary-only disease, the 12-month disease-free survival (DFS) rate was 65.8%. Overall, the results demonstrate a promising clinical efficacy signal of SIM0237 in patients with BCG-unresponsive high-risk NMIBC. In terms of safety, intravesical administration of SIM0237 demonstrated favorable safety and tolerability, and serum sample analysis showed no detectable systemic exposure to the drug.

SIM0500 (humanized GPRC5D-BCMA-CD3 trispecific antibody)

SIM0500 is a humanized trispecific antibody that targets GPRC5D-BCMA-CD3, developed independently by the Group using T-cell engager poly-specific antibody technology platform. This molecule features a low affinity/ high target-activating CD3 engaging arm and binding sites for the two tumor antigens: G-Protein-coupled receptor C class 5 member D (GPRC5D) and B-cell maturation antigen (BCMA). SIM0500 has shown strong T cell cytotoxicity against multiple myeloma (MM) cells by leveraging a combination of various antitumor effects.

In January 2025, the Group has entered into an option to license agreement with AbbVie Inc. ("**AbbVie**"), and AbbVie would have the option to license SIM0500, an IND candidate. The Group will receive an upfront payment from AbbVie, and is eligible to receive option fees and milestone payments of up to US$1.055 billion, as well as tiered royalties on net sales outside of the Greater China territory. AbbVie is eligible to receive tiered royalties on net sales in the Greater China territory. In December 2025, in addition to the upfront payment, the Group has received a further payment of US$40 million from AbbVie.

Milestone of Clinical Progress

- The Phase I clinical trial of SIM0500 as monotherapy is currently being conducted simultaneously in China and the U.S..

SIM0505 (CDH6-ADC)

CDH6, a Class II classical cadherin, is highly expressed in a variety of tumors but with very limited expression in normal tissues. SIM0505 is a CDH6-targeting ADC molecule developed by the Group, which consists of CDH6 monoclonal antibody specifically binding to tumor cells and the Group's proprietary camptothecin derivative toxin, conjugated by a linker. By combining the tumor-specific targeting antibody with the high-efficiency killing effect of toxin molecules, SIM0505 can specifically target tumor cells and reduce the toxic side effects compared to traditional chemotherapies. Such ADC is intended for the treatment of malignant tumors such as ovarian and renal cancer.

In June 2025, Simcere Zaiming Pharmaceutical Co., Ltd. (先聲再明醫藥股份有限公司) ("**Simcere Zaiming**"), a subsidiary of the Company, entered into a license agreement (the "**License Agreement**") with NextCure, Inc. ("**NextCure**"). Pursuant to the License Agreement, (i) NextCure obtains global rights (excluding the Greater China region) to SIM0505; (ii) NextCure is eligible to access Simcere Zaiming's proprietary topoisomerase I inhibitor ("**TOPOi**") payload for the research and development of a novel target ADC product in preclinical development; and (iii) Simcere Zaiming will hold the relevant rights to the novel target ADC product in Greater China.

Milestone of Clinical Progress

- In April 2026, SIM0505 was granted fast track certification by the FDA.

- SIM0505 monotherapy initiated patient enrollment for the dose optimization phase in platinum-resistant ovarian cancer.

SIM0610 (EGFR/cMET BsADC)

SIM0610 is a Bispecific Antibody-Drug Conjugate that simultaneously targets epidermal growth factor receptor ("**EGFR**") and mesenchymal-epithelial transition factor ("**cMET**"), and induces tumor cell apoptosis through intracellular release of a TOP1i. EGFR and cMET are aberrantly activated in multiple solid tumors, including non-small cell lung cancer, and activation of the cMET pathway is one of the key mechanisms underlying resistance to EGFR tyrosine kinase inhibitors (EGFR-TKIs). Through dual-target synergistic activity, SIM0610 has the potential to enhance anti-tumor efficacy and overcome drug resistance. Preclinical studies have demonstrated that SIM0610 exhibits significant anti-tumor activity across multiple tumor models.

Milestone of Clinical Progress

- In January 2026, the clinical trial of SIM0610 reached FIH.

SIM0532 (Pan-RAS)

SIM0532 is an oral, non-covalent pan-RAS inhibitor that first forms a non-covalent bond with the intracellular chaperone protein Cyclophilin A (CypA), then binding to the activated form of RAS (RAS (ON)) to form a ternary complex, thereby blocking the binding of RAS to effector molecules (such as c-RAF). It broadly and potently inhibits both wild-type and mutant type RAS signaling pathways, thus effectively killing RAS-dependent tumor cells. Preclinical data indicated that SIM0532 exhibits strong cytotoxic activity in vitro against tumor cells with RAS gene mutations and KRAS wild-type amplification. In preclinical CDX mouse models of RAS-mutated NSCLC, pancreatic adenocarcinoma and CRC, SIM0532 demonstrated superior efficacy compared to competitive products at equivalent doses. The mechanism of action and preclinical data for SIM0532 supports its potential as an effective anti-tumor drug.

Milestone of Clinical Progress

- In March 2026, the IND application of SIM0532 was approved by the NMPA.

- In May 2026, the aforementioned clinical trial reached FIH.

SIM0613 (LRRC15 ADC)

SIM0613 is a novel ADC targeting leucine-rich repeat-containing protein 15 (LRRC15). LRRC15 is highly expressed on the surface of various solid tumors and cancer-associated fibroblasts (CAF), but rarely expressed in normal cells. Upon binding to the LRRC15 protein, SIM0613 is internalized into tumor cells via endocytosis and releases its cytotoxic payload, thereby killing tumor cells while exerting minimal impact on normal cells. Specifically engineered for deep penetration into tumors and cancer-associated fibroblasts, SIM0613 has demonstrated significant tumor regression effects in multiple preclinical in vivo models.

In December 2025, Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd. (江蘇先聲再明醫藥有限公司) ("**Jiangsu Zaiming**"), a subsidiary of the Group, entered into an exclusive licensing agreement with Ipsen Pharma SAS ("**Ipsen**"), pursuant to which Ipsen will obtain exclusive global rights outside of Greater China for the development, manufacturing and commercialization of SIM0613, an LRRC15-targeting ADC developed by Jiangsu Zaiming. The Group is eligible to receive up to US$1,060 million, comprising a US$45 million upfront payment, as well as development, regulatory and commercial milestone payments. The Group is also eligible for tiered royalties on sales.

Milestone of Clinical Progress

- In May 2026, the IND application of SIM0613 was approved by the NMPA.

- In June 2026, the aforementioned clinical trial reached FIH.

ANTI-ONCOLOGY PRODUCTS

SIM0278 (IL2muFc)

SIM0278 is an Fc fusion protein (IL2muFc) with an IL2 mutein of Regulatory T cells ("**Treg**"), developed based on the Group's protein engineering technology platform. By introducing the mutation, the affinity of SIM0278 to effector T cells is reduced, while the high affinity of Treg cells is retained and then the selectivity of Treg cells is improved. In September 2022, the Group entered into a licensing agreement with Almirall S.A. ("**Almirall**"), which is an international biopharmaceutical company. Pursuant to the agreement, the Group grants Almirall an exclusive rights and interests in the development and commercialization of SIM0278 outside Greater China, and retains all rights and interests in the Greater China region.

Milestone of Clinical Progress

- In February 2026, Almirall initiated the Phase II clinical study of SIM0278 in the United States and reached FPI for the treatment of alopecia areata.

- In June 2026, the Phase II clinical study of SIM0278 commenced in China and reached FPI for the treatment of lupus nephritis.

NEUROSCIENCE PRODUCTS

SIM0811 (PLG)

SIM0811 is a new-generation small-molecule plasminogen allosteric activator with a dual mechanism of action that combines thrombolytic and anti-inflammatory effects. On the one hand, it modulates the conformation of plasminogen (PLG) to enhance the efficiency of endogenous tissue plasminogen activator (tPA), thereby accelerating thrombus dissolution. On the other hand, by inhibiting soluble epoxide hydrolase, SIM0811 exerts anti-inflammatory and antioxidant effects at the thrombus site, reducing reperfusion-induced inflammation and vascular endothelial cell damage. In preclinical studies, SIM0811 demonstrated superior thrombolytic efficacy and antioxidant activity compared with other investigational molecules of the same class. While traditional thrombolytic therapies such as tPA are limited by a narrow treatment window of approximately 4.5 hours, SIM0811 is expected to extend the therapeutic window to up to 24 hours, potentially benefiting a broader population of patients with acute ischemic stroke.

Milestone of Clinical Progress

- In January 2026, the clinical trial of SIM0811 reached FIH.

- In June 2026, the above clinical trial reached LPI.

IND PHASE/PRE-CLINICAL DRUG CANDITATES (SELECTED)

Anti-oncology Products

SIM0709 (TL1A/IL-23p19)

SIM0709 is a long-acting humanized bispecific antibody independently developed by the Group using proprietary multi-specific antibody platform. By simultaneously targeting tumor necrosis factor ligand superfamily member 15 (TL1A) and interleukin-23 (IL-23), SIM0709 blocks two core pathways involved in the onset and progression of IBD. In both in vitro primary cell studies and in vivo animal studies, SIM0709 demonstrated superior synergistic efficacy, even outperforming the combination of the two corresponding monotherapies.

Milestone of Strategic Cooperation

- In January 2026, a subsidiary of the Company, Jiangsu Simcere Pharmaceutical Co., Ltd. (先聲藥業有限公司) ("**Jiangsu Simcere**"), entered into an exclusive licensing agreement with Boehringer Ingelheim: Boehringer Ingelheim would have the exclusive global rights, outside of Greater China, of SIM0709, a TL1A/IL-23p19 bispecific antibody for inflammatory bowel disease. The Group is eligible to receive an upfront payment of EUR42 million as well as success-based development, regulatory and sales milestones of up to EUR1,016 million. The Group is also eligible for tiered royalties on net sales outside Greater China.

Anti-oncology Products

SIM0518 (ALK)

ALK and ROS1 are important members of the receptor tyrosine kinase family. Their gene fusion can lead to a continuous activation of the kinase domain, driving downstream oncogenic signal transduction. SIM0518 is an oral, new-generation and highly-selective ALK/ROS1 dual inhibitor developed by the Group. By selectively binding to the kinase domains of ALK and ROS1 fusion proteins and their key refractory mutants, it inhibits ALK/ROS1 kinase activity and downstream oncogenic signal transduction, thereby suppressing the proliferation and survival of ALK- or ROS1-dependent tumor cells. At the same time, SIM0518 exhibits stronger brain penetration and higher selectivity, and is expected to demonstrate intracranial and extracranial antitumor activity, while posing a low risk of neurological adverse reactions. SIM0518 is intended for the treatment of ALK-positive or ROS1-positive non-small cell lung cancer.

Milestone of Clinical Progress

- In August 2026, the IND application of SIM0518 has been submitted.

SIM0688 (B7H3/cMET ADC)

B7H3 and cMET are highly expressed in various solid tumors, while their expressions in normal tissues are limited. SIM0688 is a bispecific ADC molecule developed by the Group that simultaneously targets B7H3 and cMET. It consists of a monoclonal antibody targeting B7H3/cMET binding to the Group's proprietary camptothecin derivative toxin, conjugated by a linker. It can effectively inhibit tumor growth through dual-target-mediated killing and bystander effects, offering significant advantages over single-target ADCs.

FINANCIAL REVIEW

Revenue

For the six months ended June 30, 2026, the Group recorded revenue of RMB4,580 million, representing an increase of 27.8% as compared to RMB3,585 million for the same period of 2025.

Revenue of the Group was mainly derived from the therapeutic areas where its businesses are focused. Of which, revenue from the field of neuroscience was RMB2,009 million, accounting for 43.9% of the total revenue and representing an increase of 60.9% as compared to RMB1,249 million for the same period of 2025. Revenue from the field of anti-oncology was RMB925 million, accounting for 20.2% of the total revenue and representing an increase of 5.8% as compared to RMB874 million for the same period of 2025. Revenue from the field of autoimmune was RMB1,210 million, accounting for 26.4% of the total revenue and representing an increase of 37.8% as compared to RMB878 million for the same period of 2025. Revenue from other fields was RMB436 million, accounting for 9.5% of the total revenue and representing a decrease of 25.2% as compared to RMB584 million for the same period of 2025.

The expenditure on research and development activities of the Group includes research and development costs and the addition of intangible assets with in-licensed rights.

- For the six months ended June 30, 2026, the total expenditure on research and development activities of the Group amounted to RMB879 million, representing a decrease of 14.6% as compared to RMB1,029 million for the same period of 2025. The expenditure on research and development activities accounted for 19.2% of the revenue, representing a decrease of 9.5 percentage points as compared to 28.7% for the same period of 2025.

- For the six months ended June 30, 2026, the research and development costs amounted to RMB825 million, representing an increase of 30.3% as compared to RMB633 million for the same period in 2025. The research and development costs accounted for 18.0% of the revenue, representing an increase of 0.3 percentage point as compared to 17.7% for the same period of 2025.

- For the six months ended June 30, 2026, the addition of intangible assets with in-licensed rights amounted to RMB54 million, representing a decrease of 86.4% as compared to RMB396 million for the same period in 2025. The addition of intangible assets with in-licensed rights accounted for 1.2% of the revenue, representing a decrease of 9.8 percentage points as compared to 11.0% for the same period in 2025.

PROFIT ATTRIBUTABLE TO EQUITY SHAREHOLDERS OF THE COMPANY

The Group recorded a profit attributable to equity shareholders of the Company of RMB829 million for the six months ended June 30, 2026, representing an increase of 37.9% as compared to RMB601 million for the same period in 2025. Such increase in the profit attributable to equity shareholders of the Company was mainly attributable to the increase in revenue from innovative drugs and license income.

NON-HKFRS MEASURE – ADJUSTED PROFIT ATTRIBUTABLE TO EQUITY SHAREHOLDERS OF THE COMPANY

To supplement the financial information presented in accordance with HKFRS, the Group also uses adjusted profit attributable to equity shareholders of the Company as a non-HKFRS measure. Such measure is unaudited in nature and is not required by, or presented in accordance with, HKFRS. The Group defines adjusted profit attributable to equity shareholders of the Company as profit attributable to equity shareholders of the Company after adjusting the following items: (i) net realized and unrealized gains/losses on financial assets at fair value through profit or loss; (ii) net realized and unrealized gain on associates at fair value through profit or loss; (iii) interest expenses arising from redemption liabilities; and (iv) income tax effect related to the above items. The Group is of the view that the Group's management and investors may benefit from referring to such measure in assessing the financial performance of the Group's core businesses by eliminating the impacts of certain non-recurring, non-cash and/or non-operating items. However, the presentation of adjusted profit attributable to equity shareholders of the Company may not be comparable to similarly titled measures presented by other companies as it does not have a standardized meaning. The application of the non-HKFRS measure has limitations as an analytical tool, and the Shareholders and investors should not consider it in isolation from, or as substitute for analysis of, the results of operations or financial condition of the Group as reported under HKFRS.

For the six months ended June 30, 2026, the adjusted profit attributable to equity shareholders of the Company amounted to RMB964 million, representing an increase of 48.7% as compared to RMB649 million for the same period of last year.

The following table presents the Group's adjusted profit attributable to equity shareholders of the Company and the most directly comparable financial measure calculated and presented in accordance with HKFRS Accounting Standards, which is profit attributable to equity shareholders of the Company:

	Six months ended June 30	
	2026	2025
	RMB'000	*RMB'000*
	(unaudited)	(unaudited)
Profit attributable to equity shareholders of the Company	**828,720**	601,052
Add/(less):		
Net realized and unrealized losses on financial assets at fair value through profit or loss [(1)]	**96,494**	21,388
Net realized and unrealized gain on associates at fair value through profit or loss	**–**	(4,893)
Interest expenses arising from redemption liabilities [(2)]	**40,375**	34,865
Effect of corresponding income tax	**(1,191)**	(3,745)
Adjusted profit attributable to equity shareholders of the Company	**964,398**	648,667

Notes:

(1) Net realized and unrealized losses on financial assets at fair value through profit or loss arises from the remeasurement of the Group's investments in certain private companies and investment funds, listed equity securities, structured deposits and wealth management products at fair value.

(2) Interest expenses arising from redemption liabilities represent the change in the carrying amount of the financial liability issued in connection with the capital contributions in Simcere Zaiming (as defined below).

LIQUIDITY AND FINANCIAL RESOURCES

The Group maintained a sound financial position. For the six months ended June 30, 2026, the net cash generated from operating activities was RMB1,605 million, while the net cash generated from operating activities for the same period of last year was RMB863 million. Such changes were mainly due to the increase in revenue and the strengthening of the management of the collection of trade receivables for the Group in the first half of 2026. As of June 30, 2026, the Group had cash and cash equivalents of RMB3,072 million (as of December 31, 2025: RMB3,512 million), time deposits of RMB2,125 million (as of December 31, 2025: RMB814 million). As of June 30, 2026, the Group had a balance of bank loans of RMB1,058 million (as of December 31, 2025: RMB1,060 million), of which RMB1,051 million (as of December 31, 2025: RMB1,052 million) would mature within one year. As of June 30, 2026, RMB1,058 million of the Group's bank loan balances bore interest at fixed rates, and the effective interest rate range for these loans was 0.56% to 1.2% per annum.

As of June 30, 2026, the current ratio (calculated by total current assets divided by total current liabilities) of the Group was 190.2% (as of December 31, 2025: 220.9%), while the gearing ratio (calculated by total liabilities divided by total assets) was 38.6% (as of December 31, 2025: 36.1%).

Currently, the Group follows a set of funding and treasury policies to manage its capital resources and prevent risks involved. The Group expects to fund the working capital and other capital requirements from a combination of various sources, including but not limited to external financing at reasonable market rates. In order to better control and minimize the cost of funds, the treasury management activities of the Group are managed on a centralized basis.

The assets and liabilities of the Group were denominated in RMB, USD, GBP and HKD. During the Reporting Period, the Group did not employ financial derivatives or enter into foreign derivative contracts to hedge against foreign exchange risk. However, the Group manages the foreign exchange risks by closely monitoring the net exposure of foreign exchange risk to minimize the impact of foreign exchange fluctuations.

PLEDGE OF GROUP'S ASSETS

As of June 30, 2026, the Group pledged bills receivable of RMB46 million for issuance of bank acceptance bills and pledged bank deposits of RMB20 million for issuance of letter of guarantee. As of June 30, 2026, leasehold land with net book value of RMB107 million was pledged as security for banking facilities, which were not utilized as of June 30, 2026 and the pledge has been released as of the date of this announcement. Save as disclosed above, as of June 30, 2026, none of the Group's assets were pledged.

CONTINGENT LIABILITIES

As of June 30, 2026, a subsidiary of the Group had an outstanding contract dispute with a third party, which made an indemnity claim of approximately RMB25 million against the Group. The result of this dispute was yet to be finalised. Based on the legal advice and available evidences, the Directors consider it unlikely that the outcome will be unfavorable to the Group. No provision has therefore been made in respect of this dispute. Save as disclosed above, as of June 30, 2026, the Group did not have any other contingent liabilities.

SIGNIFICANT INVESTMENTS HELD

As of June 30, 2026, the Group did not hold any significant investments.

FUTURE PLANS FOR MATERIAL INVESTMENTS AND CAPITAL ASSETS

Save as disclosed in "Use of Proceeds from the Listing" and "Use of Proceeds from the Placing" in this announcement, as of June 30, 2026, the Group did not have any other future plans for material investments and capital assets.

MATERIAL ACQUISITIONS AND DISPOSALS

On March 25, 2026, Simcere Pharmaceutical Co., Ltd.* (先聲藥業有限公司) ("**Simcere Pharmaceutical**"), an indirectly wholly-owned subsidiary of the Company, entered into the Equity Transfer Agreement with Jiangsu Simcere Diagnostic Technology Co., Ltd.* (江蘇先聲診斷技術有限公司) ("**Jiangsu Simcere Diagnostic**"), pursuant to which Simcere Pharmaceutical has agreed to acquire, and Jiangsu Simcere Diagnostic has agreed to sell, the entire equity interest in Shanghai Simcere Diagnostic Technology Co., Ltd.* (上海先聲診斷技術有限公司) ("**Shanghai Simcere Diagnostic**") for a cash consideration of RMB30,763,200 (the "**Acquisition**"). Upon completion of the Acquisition, Shanghai Simcere Diagnostic will become an indirectly wholly-owned subsidiary of the Company and the financial results of Shanghai Simcere Diagnostic will be consolidated into the financial statements of the Group. The Acquisition was completed in April 2026. Shanghai Simcere Diagnostic has become an indirectly wholly-owned subsidiary of the Company, and the financial results of Shanghai Simcere Diagnostic have already been consolidated into the financial statements of the Group.

Save as disclosed above, for the six months ended June 30, 2026, the Group had no other material acquisition or disposal of subsidiaries, associates and joint ventures.

EMPLOYEES AND REMUNERATION POLICY

As of June 30, 2026, the Group had a total of 7,064 full-time employees. The Group attached great importance to the recruitment, training and retention of outstanding employees, maintaining a high standard in selecting and recruiting talents worldwide, and offered competitive compensation packages. The remuneration of employees mainly included basic salary, performance-based bonus and long-term incentives. Remuneration of the Directors and senior management who worked full time for the Company shall be determined by the remuneration and appraisal committee of the Company under the Board with reference to the principal duties, the results of performance assessment as well as the remuneration level in the market of the relevant managerial positions. During the six months ended June 30, 2026, staff costs of the Group (including emoluments of the Directors, social insurance and other benefits) amounted to RMB1,319 million. The Group established Simcere Institute, which provides employees with training on a regular basis, including orientation programs and technical training for new employees, professional and management training for middle and senior management and health and safety training across all staff. In addition, the Group has also adopted a restricted share unit ("**RSU**") scheme on May 20, 2021 (the "**2021 RSU Scheme**"), with an aim to (1) incentivise the existing and incoming directors, senior management and employees for their contribution to the Group; and (2) attract, motivate and retain skilled and experienced personnel to strive for the future development and expansion of the Group by providing them with the opportunity to own equity interests in the Company.

During the Reporting Period, the Board resolved on March 26, 2026 to grant an aggregate of 2,169,000 RSUs, representing 2,169,000 underlying Shares, to an aggregate of 54 eligible participants (all of whom are employees of the Group) under the 2021 RSU Scheme at nil consideration. For details of such grant, please refer to the announcement of Company dated March 26, 2026.

INTERIM DIVIDEND

The Board resolved not to declare any interim dividend for the six months ended June 30, 2026.

USE OF PROCEEDS FROM THE LISTING

The net proceeds from the initial public offering of the shares of the Company in October 2020 and allotment and issuance of shares of the Company pursuant to the partial exercise of the over-allotment option in November 2020 (the "**Net Proceeds**"), amounted to HK$3,513.09 million in aggregate. The proposed use of the Net Proceeds was disclosed in the prospectus of the Company dated October 13, 2020 (the "**Prospectus**").

The following table sets out the utilization of the Net Proceeds as of June 30, 2026 and the timeline for utilization:

Purpose	**Percentage of the total amount**	**Amount of Net Proceeds received** *(HK$ in million)*	**Amount of Net Proceeds utilized during the six months ended June 30, 2026** *(HK$ in million)*	**Accumulative amount of Net Proceeds utilized as of June 30, 2026** *(HK$ in million)*	**Amount of Net Proceeds unutilized as of June 30, 2026** *(HK$ in million)*	**Timeline for utilization**
Continuous research and development of the Group's selected product candidates in its strategically focused therapeutic areas	60%	2,107.85	71.06	2,107.85	–	The actual Net Proceeds have been fully utilized.
Reinforcement of the Group's sales and marketing capabilities	10%	351.31	–	351.31	–	The actual Net Proceeds have been fully utilized.
Investment in companies in the pharmaceutical or biotechnology sector	10%	351.31	–	351.31	–	The actual Net Proceeds have been fully utilized
Repayment of certain of the Group's outstanding bank loans	10%	351.31	–	351.31	–	The actual Net Proceeds have been fully utilized.
Working capital and other general corporate purposes	10%	351.31	–	351.31	–	The actual Net Proceeds have been fully utilized.
Total	**100%**	**3,513.09**	**71.06**	**3,513.09**	**–**	

For more details, please refer to the section headed "Future Plans and Use of Proceeds – Use of Proceeds" in the Prospectus and the announcements of the Company dated April 15, 2021, August 31, 2022 and December 23, 2024 (the "**Announcements**"), in relation to the change in use of the Net Proceeds from the Listing.

As of June 30, 2026, the Net Proceeds of HK$3,513.09 million have been fully utilized.

USE OF PROCEEDS FROM THE PLACING

In September 2025, the Company completed a top-up placing of 121,000,000 new shares the Company (the "**Shares**") at a price of HK$12.95 per Share (the "**Placing**"). The net proceeds (after deducting all applicable costs and expenses) from the Placing (the "**Net Proceeds from the Placing**") were approximately HK$1,553.5 million, For details, please refer to the announcements of the Company dated September 2, 2025, and September 10, 2025.

The following table sets out the utilization of the Net Proceeds from the Placing as of June 30, 2026 and the expected timeline for utilization:

Purpose	**Percentage of the total amount**	**Actual amount of the Net Proceeds from the Placing** *(HK$ in million)*	**Amount of the Net Proceeds from the Placing utilized during the six months ended June 30, 2026** *(HK$ in million)*	**Accumulated amount of the Net Proceeds from the Placing utilized as of June 30, 2026** *(HK$ in million)*	**Amount of the Net Proceeds from the Placing unutilized as of June 30, 2026** *(HK$ in million)*	**Expected timeline for utilization**
R&D-related expenditures	90%	1398.15	85.80	146.35	1,251.80	The actual Net Proceeds from the Placing are expected to be fully utilized by 2028.
Working capital and other general corporate purposes	10%	155.35	–	–	155.35	The actual Net Proceeds from the Placing are expected to be fully utilized by 2027.
Total	**100%**	**1,553.5**	**85.80**	**146.35**	**1,407.15**	

PROSPECTS

In the current financial year and future, the Group will uphold the corporate mission of "born for the patients" actively, accelerate the development of our business in China and strengthen our global innovation capabilities. Within the Company's focused therapeutic areas, we will continue to enrich and expand our portfolio of innovative drugs, so as to lay a solid foundation for sustainable development. In addition, the Group will focus on building capabilities for overseas clinical development and registration, proactively embrace the wave of AI technology, and enable AI to empower the entire workflow spanning drug discovery, clinical research, commercialization and enterprise management. We will continuously enhance R&D efficiency, provide more effective treatment options for patients, and contribute more to the health and wellbeing of the community.

OTHER INFORMATION

1. PURCHASE, SALE OR REDEMPTION OF THE COMPANY'S LISTED SECURITIES

The Directors have been granted a general mandate by the shareholders of the Company (the "**Shareholders**") at the annual general meeting of the Company held on June 13, 2025 (the "**2024 AGM**") to repurchase up to 247,469,761 shares of the Company (the "**Shares**") on the Stock Exchange, representing 10% of the total number of issued Shares as of the date of the 2024 AGM (the "**Repurchase Mandate**"). During the Reporting Period, the Company repurchased a total of 27,499,000 Shares (the "**Repurchased Shares**") on the Stock Exchange pursuant to the Repurchase Mandate at a total consideration (excluding expenses) of HK$312,470,970 (the "**Share Repurchase**"), which was funded by internal resources of the Company. As of the date of this announcement, all the Repurchased Shares were cancelled. Details of the Shares repurchased by the Company during the Reporting Period are as follows:

Month of Share Repurchase	**Total number of Shares repurchased**	**The highest purchase price per Share** ***(HK$)***	**The lowest purchase price per Share** ***(HK$)***	**Total consideration (excluding expense)** ***(HK$)***
January 2026	10,851,000	11.90	11.20	125,824,644
March 2026	1,974,000	11.33	10.94	22,032,406
May 2026	14,674,000	11.91	10.36	164,613,920
Total	27,499,000			312,470,970

The Share Repurchase was governed by section 257 of the Hong Kong Companies Ordinance. The total amount paid on the Repurchased Shares of HK$312,470,970 (equivalent to RMB276,237,000) was paid wholly out of retained profits of the Company.

The Board believes that the Share Repurchase demonstrates the Company's confidence in its own business outlook and prospects and would, ultimately, benefit the Company and create value for the Shareholders. In addition, the Board believes that the current financial resources of the Company enable it to implement the Share Repurchase while maintaining a solid financial position.

Save as disclosed above, during the Reporting Period, neither the Company nor any of its subsidiaries had purchased, sold or redeemed any of the Company's listed securities (including sale of treasury shares (if any)). The Company did not hold any treasury shares during the Reporting Period and as of June 30, 2026.

2. IMPORTANT EVENTS AFTER THE REPORTING PERIOD

After the Reporting Period and up to the date of this announcement, there were no material events affecting the Company or any of its subsidiaries.

3. COMPLIANCE WITH THE CORPORATE GOVERNANCE CODE

The Group is committed to maintaining and promoting stringent corporate governance. The principles of the Group's corporate governance are to promote effective internal control measures, uphold a high standard of ethics, transparency, responsibility and integrity in all aspects of business, so as to ensure that its business and operation are conducted in accordance with applicable laws and regulations, enhance the transparency of the Board and strengthen the accountability to all Shareholders. The Group's corporate governance practices are based on the principles and code provisions prescribed in the Corporate Governance Code (the "**CG Code**") as set out in Appendix C1 to the Rules governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**").

Save as disclosed below, the Group has complied with the code provisions contained in Part 2 of the CG Code during the Reporting Period.

Under code provision C.2.1 of Part 2 of the CG Code, the roles of chairman and chief executive officer should be separate and should not be performed by the same individual. During the period from January 1, 2026 to March 24, 2026, the roles of chairman of the Board (the "**Chairman**") and chief executive officer of the Company (the "**Chief Executive Officer**") were not separated and Mr. REN Jinsheng ("**Mr. REN**") performed these two roles. Mr. REN is the founder of the Group, the Chairman and the Chief Executive Officer. He was then primarily responsible for overall corporate business strategies and business operation of the Group and making significant business and operational decisions for the Group. The Directors jointly consider that vesting the roles of both the Chairman and the Chief Executive Officer in Mr. REN is beneficial to the business prospects of the Group by ensuring consistent leadership to the Group as well as prompt and effective decision making and implementation. In addition, the Directors jointly believe that this structure will not impair the balance of power and authority between the Board and the management of the Company, given that: (i) any decision to be made by the Board requires approval by at least a majority of the Directors; (ii) Mr. REN and other Directors are aware of and undertake to fulfill their fiduciary duties as the Directors, which require, among other things, that he acts for the benefit and in the best interests of the Company and will make decisions for the Company accordingly; (iii) the balance of power and authority is ensured by the operations of the Board, which consists of four executive Directors (including Mr. REN) and four independent non-executive Directors, and has a fairly strong independence element; and (iv) the overall strategic and other key business, financial, and operational policies of the Company are made collectively after thorough discussion at both Board and senior management levels.

4. COMPLIANCE WITH THE MODEL CODE FOR SECURITIES TRANSACTIONS BY DIRECTORS

The Group has adopted the Model Code for Securities Transactions by Directors of Listed Issuers (the "**Model Code**") as set out in Appendix C3 to the Listing Rules as the Group's code of conduct regarding the Directors' securities transactions. Having made specific enquiries of all the Directors, all the Directors confirmed that they have strictly complied with the Model Code during the Reporting Period.

5. AUDIT COMMITTEE AND REVIEW OF FINANCIAL INFORMATION

The Group established the Audit Committee with written terms of reference in compliance with the CG Code. The main duties of the Audit Committee are to review and supervise the financial reporting process and internal control system of the Group, oversee the audit process, review and oversee the existing and potential risks of the Group and perform other duties and responsibilities as assigned by the Board.

As of the date of this announcement, the Audit Committee consists of three members, all of which are independent non-executive Directors, namely Mr. WANG Xinhua, Mr. SONG Ruilin and Mr. WANG Jianguo. The chairperson of the Audit Committee is Mr. WANG Xinhua, who possesses the appropriate professional qualifications and accounting and related financial management expertise.

The Audit Committee has reviewed the financial reporting processes, risk management and internal control systems of the Group and the unaudited condensed consolidated interim financial statements and interim report of the Group for the six months ended June 30, 2026, and is of the opinion that these statements have complied with the applicable accounting standards, the Listing Rules and legal requirements, and that adequate disclosure has been made.

6. INDEPENDENT REVIEW OF AUDITOR

The interim financial report for the six months ended June 30, 2026 is unaudited, but has been reviewed by KPMG, in accordance with Hong Kong Standard on Review Engagements No.2410 "*Review of interim financial information performed by the independent auditor of the entity*" issued by the Hong Kong Institute of Certified Public Accountants, whose unmodified review report is included in the 2026 interim report to be sent to the Shareholders.

7. REASSIGNMENT OF EXECUTIVE ROLES

Change of Chief Executive Officer

The Board hereby announces that, in order to further accelerate the development of our business in China and strengthen our global innovation capabilities, upon Dr. Zhou's recommendation and with the Board's approval, Mr. Ren will serve as the Chief Executive Officer and continue to serve as the Chairman and an Executive Director, while Dr. Zhou will serve as the President of the Company, with effect from August 20, 2026. Dr. Zhou has confirmed that he has no disagreement with the Board and there is no other matter in relation to his change of role that needs to be brought to the attention of the shareholders.

This appointment is coterminous with Mr. Ren tenure as an executive Director, and no additional remuneration will be payable to Mr. REN in connection with his role as the Chief Executive Officer. As at the date of this announcement, Mr. REN was interested and deemed to be interested in 1,731,390,215 Shares pursuant to Part XV of the SFO.

Save as disclosed in the Company's 2025 annual report and above and as at the date of this announcement, Mr. REN has confirmed that (i) he does not have any relationship with any Directors, senior management or substantial or controlling shareholders of the Company; (ii) he does not hold any directorships in other listed companies the securities of which are listed on any securities market in Hong Kong or overseas in the past three years; (iii) he does not have, or is not deemed to have, any interests or short positions in any shares, underlying shares or debentures as defined under Part XV of the Securities and Futures Ordinance; (iv) there is no other information that is required to be disclosed pursuant to any of the requirements under Rules 13.51(2)(h) to (v) of the Listing Rules; and (v) there are no other matters concerning the appointment of him as the Chief Executive Officer that need to be brought to the attention of the Shareholders.

Re-designation of Director

Reference is made to the announcement of the Company dated January 9, 2026 in relation to the proposed spin-off and separate listing of Simcere Zaiming Pharmaceutical Co., Ltd. ("**Simcere Zaiming**") on the Main Board of the Stock Exchange (the "**Proposed Spin-off**").

In light of the Proposed Spin-off, Dr. TANG Renhong ("**Dr. TANG**") has been re-designated from an executive Director to a non-executive Director with effect from August 20, 2026. Dr. TANG will continue to serve as the chairman of the board of directors, an executive director and the chief executive officer of Simcere Zaiming.

Dr. TANG will remain as a non-executive Director and be available to give advice and share R&D experience, and jointly formulate the Group's overall corporate strategy, objectives, and direction.

8. PUBLICATION OF THE INTERIM RESULTS ANNOUNCEMENT AND INTERIM REPORT

This interim results announcement is published on the websites of the Stock Exchange (www.hkexnews.hk) as well as the Group (www.simcere.com), respectively. The Group's 2026 interim report will be published on the aforementioned websites in due course.

CONSOLIDATED STATEMENT OF PROFIT OR LOSS

for the six months ended June 30, 2026 – unaudited

		Six months ended June 30,	
		2026	2025
	Note	***RMB'000***	*RMB'000*
			(restated)
Revenue	*4*	**4,580,142**	3,584,912
Cost of sales		**(765,105)**	(691,062)
Gross profit		**3,815,037**	2,893,850
Other income	*5(a)*	**85,890**	68,223
Other net loss	*5(b)*	**(71,880)**	(29,814)
Research and development costs		**(824,922)**	(633,190)
Selling and distribution expenses		**(1,707,916)**	(1,350,545)
Administrative and other operating expenses		**(321,981)**	(265,639)
Provision for impairment loss on trade and other receivables		**(4,123)**	(827)
Profit from operations		**970,105**	682,058
Finance income	*6(a)*	**48,394**	26,581
Finance costs	*6(a)*	**(8,851)**	(13,671)
Interest expenses arising from redemption liabilities	*6(a)*	**(40,375)**	(34,865)
Net finance costs		**(832)**	(21,955)
Share of losses of associates		**(1,282)**	(1,908)
Share of (losses)/profits of joint ventures		**(1,273)**	1,735
Profit before taxation	*6*	**966,718**	659,930
Income tax	*7*	**(140,182)**	(58,878)
Profit for the period		**826,536**	601,052

CONSOLIDATED STATEMENT OF PROFIT OR LOSS (CONTINUED)

for the six months ended June 30, 2026 – unaudited

		Six months ended June 30,	
		2026	2025
	Note	***RMB'000***	*RMB'000*
			(restated)
Attributable to:			
Equity shareholders of the Company		**828,720**	601,052
Non-controlling interests		**(2,184)**	–
Profit for the period		**826,536**	601,052
Earnings per share	*8*		
Basic and diluted (RMB)		**0.32**	0.25

CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

for the six months ended June 30, 2026 – unaudited

	Six months ended June 30,	
	2026	2025
	RMB'000	*RMB'000*
		(restated)
Profit for the period	**826,536**	601,052
Other comprehensive income for the period (after tax adjustments)		
Items that will not be reclassified to profit or loss:		
Financial assets at fair value through other comprehensive income – net movement in fair value reserves (non-recycling), net of tax	**(9,925)**	7,574
Exchange difference on translation of company level financial statements	**(93,412)**	(20,005)
Items that are or may be reclassified subsequently to profit or loss:		
Exchange difference on translation of financial statements of overseas subsidiaries	**(24,119)**	(1,445)
Other comprehensive income for the period	**(127,456)**	(13,876)
Total comprehensive income for the period	**699,080**	587,176
Attributable to:		
Equity shareholders of the Company	**701,276**	587,176
Non-controlling interests	**(2,196)**	–
Total comprehensive income for the period	**699,080**	587,176

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

at June 30, 2026 – unaudited

	Note	**June 30, 2026** ***RMB'000***	December 31, 2025 *RMB'000*
Non-current assets			
Property, plant and equipment		**2,738,954**	2,531,632
Intangible assets		**1,481,245**	1,442,592
Goodwill		**142,474**	142,474
Interest in associates		**57,213**	58,712
Interest in joint ventures		**102,509**	104,188
Prepayments, deposits and other receivables		**211,863**	346,025
Financial assets at fair value through other comprehensive income ("**FVOCI**")		**285,686**	297,365
Financial assets at fair value through profit or loss ("**FVPL**")		**1,200,984**	1,143,560
Time deposits	*10(c)*	**1,170,119**	748,603
Deferred tax assets		**603,479**	520,711
		7,994,526	7,335,862
Current assets			
Inventories		**632,911**	589,495
Contract assets		**10,810**	19,565
Trade and bills receivables	*9*	**2,396,674**	2,838,454
Prepayments, deposits and other receivables		**250,097**	222,449
Loan to a third party		**100,096**	100,105
Tax recoverable		**19,002**	4,744
Pledged deposits	*10(b)*	**19,675**	23,340
Restricted deposits	*10(b)*	**9,904**	14,003
Time deposits	*10(c)*	**955,306**	65,528
Cash and cash equivalents	*10(a)*	**3,072,182**	3,512,088
		7,466,657	7,389,771

CONSOLIDATED STATEMENT OF FINANCIAL POSITION (CONTINUED)

at June 30, 2026 – unaudited

	Note	**June 30, 2026**	December 31, 2025
		RMB'000	*RMB'000*
Current liabilities			
Bank loans	*11*	**1,051,058**	1,052,478
Lease liabilities		**56,228**	57,341
Trade and bills payables	*12*	**239,151**	249,032
Other payables and accruals	*13*	**2,468,978**	1,898,494
Taxation payable		**88,420**	65,704
Provisions		**22,000**	22,000
		3,925,835	3,345,049
Net current assets		**3,540,822**	4,044,722
Total assets less current liabilities		**11,535,348**	11,380,584
Non-current liabilities			
Bank loans	*11*	**6,932**	7,479
Lease liabilities		**58,151**	69,635
Deferred income		**513,709**	472,528
Deferred tax liabilities		**80,305**	68,035
Other financial liability		**1,223,692**	1,183,317
Other non-current liability		**165,000**	165,000
		2,047,789	1,965,994
NET ASSETS		**9,487,559**	9,414,590

CONSOLIDATED STATEMENT OF FINANCIAL POSITION (CONTINUED)

at June 30, 2026 – unaudited

	June 30, 2026	December 31, 2025
	RMB'000	*RMB'000*
CAPITAL AND RESERVES		
Share capital	**4,626,780**	4,618,517
Reserves	**4,797,472**	4,789,349
Total equity attributable to equity shareholders of the Company	**9,424,252**	9,407,866
Non-controlling interests	**63,307**	6,724
TOTAL EQUITY	**9,487,559**	9,414,590

NOTES TO THE UNAUDITED INTERIM FINANCIAL REPORT

(Expressed in Renminbi unless otherwise indicated)

1 GENERAL INFORMATION

Simcere Pharmaceutical Group Limited (the "**Company**") was incorporated in Hong Kong on November 30, 2015 as a limited liability company with its registered office at Room 703, 7/F, Block 20E, Hong Kong Science Park Phase 3, Pak Shek Kok, New Territories, Hong Kong. The Company's shares were listed on the Main Board of the Stock Exchange of Hong Kong Limited on October 27, 2020. The Company is an investment holding company. The Company and its subsidiaries (together, "**the Group**") are principally engaged in the research and development, manufacturing and sales of pharmaceutical products as well as rendering commercialization service of pharmaceutical products that are not manufactured by the Group.

2 BASIS OF PREPARATION

This interim financial report has been prepared in accordance with the applicable disclosure provisions of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, including compliance with Hong Kong Accounting Standard ("**HKAS**") 34, *Interim financial reporting*, issued by the Hong Kong Institute of Certified Public Accountants ("**HKICPA**").

The interim financial report has been prepared in accordance with the same accounting policies adopted in the 2025 annual financial statements, except for the accounting policy changes that are expected to be reflected in the 2026 annual financial statements. Details of any changes in accounting policies are set out in Note 3.

The preparation of an interim financial report in conformity with HKAS 34 requires management to make judgements, estimates and assumptions that affect the application of policies and reported amounts of assets and liabilities, income and expenses on a year-to-date basis. Actual results may differ from these estimates.

This interim financial report contains condensed consolidated financial statements and selected explanatory notes. The notes include an explanation of events and transactions that are significant to an understanding of the changes in financial position and performance of the Group since the 2025 annual financial statements. The condensed consolidated interim financial statements and the accompanying notes do not include all of the information required for a full set of financial statements prepared in accordance with HKFRS Accounting Standards.

The interim financial report is unaudited, but has been reviewed by KPMG in accordance with Hong Kong Standard on Review Engagements 2410, *Review of interim financial information performed by the independent auditor of the entity*, issued by the HKICPA.

The financial information relating to the financial year ended December 31, 2025 that is included in the interim financial report as comparative information does not constitute the Company's statutory annual consolidated financial statements for that financial year but is derived from those financial statements. Further information relating to these statutory financial statements disclosed in accordance with section 436 of the Hong Kong Companies Ordinance (Cap. 622) is as follows:

The Company has delivered the financial statements for the year ended December 31, 2025 to the Registrar of Companies as required by section 662(3) of, and Part 3 of Schedule 6 to, the Companies Ordinance.

The Company's auditor has reported on those financial statements. The auditor's report was unqualified; did not include a reference to any matters to which the auditor drew attention by way of emphasis without qualifying its report; and did not contain a statement under section 406(2), 407(2) or (3) of the Companies Ordinance.

3 CHANGES IN ACCOUNTING POLICIES

The HKICPA has issued a number of amendments to HKFRS Accounting Standards that are first effective for the current accounting period. None of these developments have had a material effect on these financial statements. The Group has not applied any new standard or interpretation that is not yet effective for the current accounting period.

4 REVENUE AND SEGMENT REPORTING

(a) Revenue

Disaggregation of revenue by business lines is as follows:

	Six months ended June 30,	
	2026	2025
	RMB'000	*RMB'000*
Sales of pharmaceutical products	**3,893,202**	3,257,304
Income from commercialization business		
– Commercialisation service income	**112,202**	103,660
– Collaborative arrangements	**154,934**	80,492
License income	**405,007**	121,987
Research service income	**9,641**	21,469
Others	**5,156**	–
	4,580,142	3,584,912

The Group's revenue from contracts with customers were recognized at point in time with the amount of RMB4,570,501,000 (six months ended June 30, 2025: RMB3,563,443,000) and were recognized over time with the amount of RMB9,641,000 (six months ended June 30, 2025: RMB21,469,000).

(b) Information about profit or loss, assets and liabilities

Information about reportable segments as provided to the Group's most senior executive management for resource allocation and performance assessment for the period, are set out below.

	Six months ended June 30, 2026		
	Anti-oncology business	**Other pharmaceuticals business**	**Total**
	RMB'000	***RMB'000***	***RMB'000***
Revenue from external customers	**924,800**	**3,655,342**	**4,580,142**
Intersegment revenue	**20,457**	**23,722**	**44,179**
Reportable segment revenue	**945,257**	**3,679,064**	**4,624,321**
Reportable segment net (loss)/profit	**(209,435)**	**1,317,513**	**1,108,078**

4 REVENUE AND SEGMENT REPORTING (CONTINUED)

(b) Information about profit or loss, assets and liabilities (continued)

	Six months ended June 30, 2025		
	Anti-oncology business	Other pharmaceuticals business	Total
	RMB'000	*RMB'000*	*RMB'000*
Revenue from external customers	874,513	2,710,399	3,584,912
Intersegment revenue	6,091	31,539	37,630
Reportable segment revenue	880,604	2,741,938	3,622,542
Reportable segment net (loss)/profit	(204,485)	914,691	710,206

	As at 30 June 2026		
	Anti-oncology business	**Other pharmaceuticals business**	**Total**
	RMB'000	***RMB'000***	***RMB'000***
Reportable segment assets	**3,852,150**	**10,010,008**	**13,862,158**

	As at 31 December 2025		
	Anti-oncology business	Other pharmaceuticals business	Total
	RMB'000	*RMB'000*	*RMB'000*
Reportable segment assets	3,888,560	9,257,019	13,145,579

(c) Reconciliations of reportable segment profit or loss

	Six months ended June 30,	
	2026	2025
	RMB'000	*RMB'000 (restated) (Note 24)*
Profit		
Reportable segment profit	**1,108,078**	710,206
Intersegment elimination	**(1,936)**	1,257
Net realized and unrealized losses on financial assets at FVPL	**(96,494)**	(21,388)
Net realized and unrealized gain on interest in associates at FVPL	**–**	4,893
Interest expenses arising from redemption liabilities	**(40,375)**	(34,865)
Share of losses of associates	**(1,282)**	(1,908)
Share of (losses)/profits of joint ventures	**(1,273)**	1,735
Consolidated profit before taxation	**966,718**	659,930

5 OTHER INCOME AND OTHER NET LOSS

(a) Other income

	Six months ended June 30,	
	2026	2025
	RMB'000	*RMB'000*
		(restated)
Government grants	**77,321**	61,820
Rental income	**2,397**	914
Property management income	**177**	194
Consulting and technology service income	**5,587**	4,108
Others	**408**	1,187
	85,890	68,223

(b) Other net loss

	Six months ended June 30,	
	2026	2025
	RMB'000	*RMB'000*
Net foreign exchange gain	**24,620**	7,872
Net loss on disposal of property, plant and equipment	**(6)**	(259)
Net realized and unrealized losses on financial assets at FVPL	**(96,494)**	(21,388)
Net realized and unrealized gain on interest in associates at FVPL	**–**	4,893
Loss on litigations	**–**	(20,932)
	(71,880)	(29,814)

6 PROFIT BEFORE TAXATION

Profit before taxation is arrived at after charging/(crediting):

(a) Net finance costs

	Six months ended June 30,	
	2026	2025
	RMB'000	*RMB'000*
		(restated)
Interest income from bank deposits	**(46,651)**	(24,838)
Interest income from loan to a third party	**(1,743)**	(1,743)
Finance income	**(48,394)**	(26,581)
Interest expenses on bank loans	**7,121**	11,012
Interest expenses on lease liabilities	**1,730**	2,659
Finance costs	**8,851**	13,671
Interest expenses arising from redemption liabilities	**40,375**	34,865
Net finance costs	**832**	21,955

(b) Other items

	Six months ended June 30,	
	2026	2025
	RMB'000	*RMB'000*
		(restated)
Depreciation charge		
– owned property, plant and equipment	**98,439**	105,219
– right-of-use assets	**38,518**	38,556
Amortization of intangible assets	**71,656**	32,149
Provision for write-down of inventories	**53,129**	39,067

7 INCOME TAX

Taxation in the consolidated statement of profit or loss represents:

	Six months ended June 30,	
	2026	2025
	RMB'000	*RMB'000*
Current tax		
PRC Corporate Income Tax		
Provision for the period	**201,883**	136,305
Under-provision/(over-provision) in respect of prior years	**10,216**	(8,766)
	212,099	127,539
Overseas corporate income tax		
Provision for the period	**260**	298
Deferred tax		
Origination and reversal of temporary differences	**(72,177)**	(68,959)
	140,182	58,878

The provision for PRC Corporate Income Tax is based on the respective corporate income tax rates applicable to the subsidiaries located in the PRC as determined in accordance with the relevant income tax rules and regulations of the PRC.

Taxation for overseas subsidiaries is similarly calculated using the estimated annual effective rates of taxation that are expected to be applicable in the relevant countries.

8 EARNINGS PER SHARE

(a) Basic earnings per share

The calculation of basic earnings per share is based on the profit attributable to ordinary equity shareholders of the Company of RMB828,720,000 (six months ended June 30, 2025: RMB601,052,000, as restated) and the weighted average of 2,551,796,123 ordinary shares (six months ended June 30, 2025: 2,443,816,068 ordinary shares) in issue during the interim period.

Weighted average number of ordinary shares

	Six months ended June 30,	
	2026	2025
Issued ordinary shares at January 1	**2,595,697,618**	2,486,320,618
Effect of purchase of own shares	**(15,530,011)**	(9,110,071)
Effect of vested shares under 2021 RSU Scheme	**657,022**	742,568
Effect of unvested shares under 2021 RSU Scheme	**(29,028,506)**	(34,137,047)
Weighted average number of ordinary shares at June 30	**2,551,796,123**	2,443,816,068

(b) Diluted earnings per share

The calculation of diluted earnings per share is based on the profit attributable to ordinary equity shareholders of the Company of RMB828,720,000 (six months ended June 30, 2025: RMB601,052,000, as restated) and the weighted average of 2,557,053,323 ordinary shares (six months ended June 30, 2025: 2,447,249,758 shares).

Weighted average number of ordinary shares (diluted)

	Six months ended June 30,	
	2026	2025
Weighted average number of ordinary shares at June 30	**2,551,796,123**	2,443,816,068
Effect of contingently issuable shares under 2021 RSU scheme	**5,257,200**	3,433,690
Weighted average number of ordinary shares (diluted) at June 30	**2,557,053,323**	2,447,249,758

9 TRADE AND BILLS RECEIVABLES

	June 30, 2026	December 31, 2025
	RMB'000	*RMB'000*
Trade receivables	**2,008,007**	2,493,990
Bills receivable	**406,198**	357,876
	2,414,205	2,851,866
Less: loss allowance	**(17,531)**	(13,412)
	2,396,674	2,838,454

All of the trade and bills receivables are expected to be recovered within one year.

As at June 30, 2026, bills receivable of RMB46,117,000 were pledged for issuance of bills payable (2025: RMB34,627,000).

Aging analysis

As of the end of the reporting period, the aging analysis of trade and bills receivables, based on the invoice date and net of loss allowance, is as follows:

	June 30, 2026	December 31, 2025
	RMB'000	*RMB'000*
Within 3 months	**2,098,416**	2,440,888
Over 3 months but within 6 months	**286,373**	372,454
Over 6 months but within 9 months	**11,879**	23,476
Over 9 months but within 12 months	**6**	1,636
	2,396,674	2,838,454

Trade receivables are due within 30 – 90 days from the date of billing.

10 CASH AND CASH EQUIVALENTS, TIME DEPOSITS, PLEDGED DEPOSITS AND RESTRICTED DEPOSITS

(a) Cash and cash equivalents comprise:

	June 30, 2026	December 31, 2025
	RMB'000	*RMB'000*
Cash at bank	**3,072,182**	3,512,088

As of the end of the reporting period, cash and cash equivalents located in Chinese Mainland amounted to RMB1,693,280,000 (2025: RMB2,032,370,000). Remittance of funds out of Chinese Mainland is subject to relevant rules and regulations of foreign exchange control.

(b) Pledged deposits and restricted deposits comprise:

	June 30, 2026	December 31, 2025
	RMB'000	*RMB'000*
Pledged deposits for		
– issuance of letter of guarantee	**19,675**	23,340

	June 30, 2026	December 31, 2025
	RMB'000	*RMB'000*
Restricted deposits for		
– research and development projects	**8,698**	12,797
– litigations	**1,206**	1,206
	9,904	14,003

(c) Time deposits:

	June 30, 2026	December 31, 2025
	RMB'000	*RMB'000*
Current portion	**955,306**	65,528
Non-current portion	**1,170,119**	748,603
	2,125,425	814,131

11 BANK LOANS

The maturity profile for the interest-bearing bank loans of the Group at the end of each reporting period is as follows:

	June 30, 2026	December 31, 2025
	RMB'000	*RMB'000*
Short-term bank loans	**1,050,380**	1,051,778
Current portion of long-term bank loans	**678**	700
Within 1 year or on demand	**1,051,058**	1,052,478
After 1 year but within 2 years	**630**	650
After 2 years but within 5 years	**1,890**	1,950
After 5 years	**4,412**	4,879
	6,932	7,479
	1,057,990	1,059,957

As at June 30, 2026 and December 31, 2025, the bank loans were unsecured.

12 TRADE AND BILLS PAYABLES

	June 30, 2026	December 31, 2025
	RMB'000	*RMB'000*
Trade payables	**193,732**	240,520
Bills payable	**45,419**	8,512
	239,151	249,032

As of the end of the reporting period, the aging analysis of trade and bills payables, based on the invoice date, is as follows:

	June 30, 2026	December 31, 2025
`	***RMB'000***	*RMB'000*
Within 3 months	**175,224**	190,312
3 to 12 months	**57,179**	55,161
Over 12 months	**6,748**	3,559
	239,151	249,032

All of the trade and bills payables are expected to be settled within one year or repayable on demand.

13 OTHER PAYABLES AND ACCRUALS

	June 30, 2026	December 31, 2025
	RMB'000	*RMB'000*
Accrued expenses *(Note i)*	**504,688**	335,588
Contract liabilities *(Note ii)*	**676,309**	687,056
Payable for employee reimbursements	**15,998**	16,091
Payables for staff related costs	**388,743**	380,011
Payables for acquisition of property, plant and equipment	**162,167**	131,628
Dividends payable	**457,268**	–
Other tax payables	**122,870**	185,786
Payables for research and development costs	**49,291**	81,746
Others	**91,644**	80,588
	2,468,978	1,898,494

Notes:

(i) Accrued expenses primarily comprise marketing and promotion expenses, research and development costs and other expenses.

(ii) Contract liabilities represent customers' advances received for goods that have not yet been transferred to the customers.

14 DIVIDENDS

Dividends payable to equity shareholders of the Company attributable to the previous financial years, declared and approved during the period:

	Six months ended June 30,	
	2026	2025
	RMB'000	*RMB'000*
Dividends in respect of previous financial years declared and approved during the interim period, RMB0.18 per share (six months ended June 30, 2025: RMB0.16 per share)	**462,276**	395,952
Less: Dividends attributable to unvested shares under 2021 RSU scheme	**(5,008)**	(5,206)
	457,268	390,746

The directors did not recommend payment of interim dividends for the six months ended June 30, 2026 and 2025.

By order of the Board
Simcere Pharmaceutical Group Limited
Mr. REN Jinsheng
Chairman and Chief Executive Officer

Hong Kong, August 20, 2026

As at the date of this announcement, the Board comprises Mr. REN Jinsheng as the Chairman and executive Director; Mr. WAN Yushan and Ms. WANG Xi as the executive Directors; Mr. TANG Renhong as the non-executive Director; and Mr. SONG Ruilin, Mr. WANG Jianguo, Mr. WANG Xinhua and Mr. SUNG Ka Woon as the independent non-executive Directors.